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Abstract
Background: Type 2 diabetes mellitus (T2DM) and several types of neurodegeneration, including Alzheimer’s, are
linked to insulin-resistance, and chronic high dietary fat intake causes T2DM with mild neurodegeneration. Intra-
cerebral Streptozotocin, a nitrosamine-related compound, causes neurodegeneration, whereas peripheral treatment
causes DM.
Hypothesis: Limited early exposures to nitrosamines that are widely present in the environment, enhance the
deleterious effects of high fat intake in promoting T2DM and neurodegeneration.
Methods: Long Evans rat pups were treated with N-nitrosodiethylamine (NDEA) by i.p. injection, and upon
weaning, they were fed with high fat (60%; HFD) or low fat (5%; LFD) chow for 8 weeks. Cerebella were harvested
to assess gene expression, and insulin and insulin-like growth factor (IGF) deficiency and resistance in the context
of neurodegeneration.
Results: HFD ± NDEA caused T2DM, neurodegeneration with impairments in brain insulin, insulin receptor, IGF-2
receptor, or insulin receptor substrate gene expression, and reduced expression of tau and choline acetyltransferase
(ChAT), which are regulated by insulin and IGF-1. In addition, increased levels of 4-hydroxynonenal and
nitrotyrosine were measured in cerebella of HFD ± NDEA treated rats, and overall, NDEA+HFD treatment reduced
brain levels of Tau, phospho-GSK-3b (reflecting increased GSK-3b activity), glial fibrillary acidic protein, and ChAT to
greater degrees than either treatment alone. Finally, pro-ceramide genes, examined because ceramides cause
insulin resistance, oxidative stress, and neurodegeneration, were significantly up-regulated by HFD and/or NDEA
exposure, but the highest levels were generally present in brains of HFD+NDEA treated rats.
Conclusions: Early limited exposure to nitrosamines exacerbates the adverse effects of later chronic high dietary
fat intake in promoting T2DM and neurodegeneration. The mechanism involves increased generation of ceramides
and probably other toxic lipids in brain.
Background
The prevalence rates of Alzheimer’sD i s e a s e( A D ) ,P a r -
kinson’s disease (PD), obesity, type 2 diabetes mellitus
(T2DM), and metabolic syndrome have increased expo-
nentially over the past several decades, and thus far
show few hints of plateau [1-4]. The relatively short
time interval flanking dramatic shifts in age-adjusted
AD and PD mortality is consistent with exposure-related
rather than genetic etiologies of these diseases. We have
noted that the striking increases in AD and PD mortal-
ity rates followed sharply increased consumption of pro-
cessed foods, use of preservatives, and demand for
nitrogen-containing fertilizers [4]. A common theme
resonating from these unnecessary lifestyle trends is that
we have inadvertently increased our chronic exposures
to nitrosamines (R1N(-R2)-N = O) and related
compounds.
Nitrosamines form by chemical reactions between
nitrites and secondary amines or proteins. Nitrosamines
exert their toxic and mutagenic effects by alkylating N-7
of guanine, leading to increased DNA damage [5] and
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any medium, provided the original work is properly cited.generation of reactive oxygen species such as superoxide
(O2-) and hydrogen peroxide (H2O2). Consequences
include increased lipid peroxidation, protein adduct for-
mation, and pro-inflammatory cytokine activation [6].
Of note is that these very same molecular and biochem-
ical pathogenic cascades are activated in major human
insulin-resistance diseases, including T2DM, non-alco-
holic steatohepatitis (NASH), and AD [7-13]. The con-
cept that chronic injury caused by exposure to
alkylating agents could result in malignancy and/or tis-
sue degeneration is not far-fetched given the facts that:
1) chronic exposures to tobacco nitrosamines cause
both lung cancer and emphysema; and 2) treatment
with streptozotocin (STZ), a nitrosamine-related com-
pound, causes hepatocellular carcinoma, pancreatic car-
cinoma, malignant brain tumors, T2DM, AD-type
neurodegeneration, and/or hepatic steatosis, depending
on dose and route of administration [14-22]. Therefore,
although research on nitrosamine-related compounds
has been focused on their mutagenic properties, thor-
ough characterization of their non-neoplastic and
degenerative effects is clearly warranted. In this regard,
guidance may be obtained from what is already known
about STZ-induced diseases.
STZ, like other N-nitroso compounds, causes cellular
injury and disease by functioning as: 1) an alkylating
agent and potent mutagen [14]; 2) an inducer of DNA
adducts leading to increased apoptosis [23]; 3) a media-
tor of unscheduled DNA synthesis, triggering cell death
[14]; 4) an inducer of single-strand DNA breaks and sti-
mulus for nitric oxide (NO) formation following break-
down of its nitrosamine group [16]; and 5) an enhancer
of the xanthine oxidase system leading to increased pro-
duction of superoxide anion, H2O2,a n dO H
- radicals
[24]. Ultimately, STZ-induced cellular injury, DNA
damage, and oxidative stress cause mitochondrial dys-
function [16], ATP deficiency [25] and apoptosis. The
structural similarities between STZ and nitrosamines,
including N-nitrosodiethylamine (NDEA) and N-nitro-
sodimethylamine (NDMA) [26], together with experi-
mental evidence that high doses of STZ cause cancer
while lower doses cause diabetes or AD-type neurode-
generation with cognitive impairment [15,16,22] led us
to hypothesize that while high doses of environmental
and consumed nitrosamines cause cancer, lower, sub-
mutagenic doses may promote insulin-resistance
mediated degenerative diseases, including T2DM, AD,
and possibly other neurological diseases.
A n o t h e rk e yp o i n ti st h a to b e s i t y ,T 2 D M ,a n dc o g n i -
tive impairment are likely inter-related, as suggested by
the findings of: 1) increased risk for developing mild
cognitive impairment (MCI), dementia, or AD in indivi-
duals with T2DM [7,27] or obesity/dyslipidemic disor-
ders [28]; 2) progressive brain insulin resistance and
insulin deficiency in AD [29-32]; 3) cognitive impair-
ment in experimental animal models of T2DM and/or
obesity [33,34]; 4) AD-type neurodegeneration and cog-
nitive impairment in experimentally induced brain insu-
lin resistance and insulin deficiency [21,22,35-37]; 5)
improved cognitive performance in experimental models
of AD [19] and in human subjects with AD or MCI
after treatment with insulin sensitizer agents or intrana-
sal insulin [38-44]; and 6) similar molecular, biochem-
ical, and mechanistic abnormalities in T2DM and AD
[7-13]. On the other hand, recent studies showed that
HFD feeding causes obesity, T2DM, and cognitive
impairment, but is not sufficient to cause AD [45,46].
Therefore, it’s likely that chronic HFD feeding which
results in peripheral insulin resistance may provide a
second-hit, and that combined with low-dose nitrosa-
mine or other environmental exposures, it may increase
the severity of neurodegeneration.
In the present study, we examined the hypothesis that
chronic HFD feeding and limited exposure to sub-muta-
genic doses of NDEA function additively to cause insu-
lin resistance with T2DM and neurodegeneration. We
focused our investigations on the cerebellum because,
apart from subcortical neurodegenerative diseases such
as multiple system atrophy (MSA) [47-51], progressive
supranuclear palsy (PSP) [52], cerebellar ataxias
[48,53,54], PD [52,55], and motor neuron disease
(MND) [56], in which cognitive impairment has been
linked to cerebellar degeneration, there is growing evi-
dence that cerebellar degeneration is also a feature of
AD [57-59], Lewy body dementia (LBD) [60,61], and
fronto-temporal dementia [62]. Although cerebellar
degeneration in AD can be caused by superimposed PSP
[63], MSA [64], or MND [65], it often occurs indepen-
dently. Cerebellar degeneration in AD is manifested
clinically by gait instability and increased falling [66],
and structurally, by significant atrophy of the posterior
cerebellar lobes, which correlates with cognitive impair-
ment [67]. The major histopathological features of AD
cerebellar atrophy include, reductions in Purkinje cell
population, atrophy of the molecular and granule cell
layers [68], increased amyloid deposition and gliosis
in the cortex [69]; increased ubiquitin-immunoreactivity
in senile plaques and degenerating neurites [70];
extensive abnormalities in dendritic spine density and
synaptic structure in vestibulocerebellar, visual, and
auditory pathways [71,72]; and degeneration of cerebel-
lar white matter fibers with loss of climbing fibers and
presynaptic varicosities [73]. In aggregate, synaptic
pathology, rather than neurofibrillary tangles and
plaques, represents the main correlate of cerebellar
degeneration in AD.
In addition, cerebellar degeneration can be caused by
systemic diseases such as diabetes mellitus [74], chronic
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[45,46]. These systemic diseases share in common with
primary central nervous system (CNS) degenerative dis-
eases, impairments in cognition, and deficits in insulin
and IGF signaling mechanisms, insulin/IGF responsive
gene expression, and energy metabolism (glucose utiliza-
tion) in the brain, including cerebellum [29,75-78].
Therefore, understanding the mechanisms by which life-
style and environmental mediators promote neurode-
generation of the cerebellum has relevance to a broad
spectrum of human CNS diseases.
Methods
Materials
Rabbit, mouse, or goat generated monoclonal or poly-
clonal antibodies to ubiquitin, tau, phospho-tau (AT8-
S199, S202, T205), glial fibrillary acidic protein (GFAP),
4-hydroxy-2-nonenal (HNE), choline acetyltransferase
(ChAT), amyloid precursor protein amyloid-b peptide
(AbPP-Ab), b-actin, were purchased from Chemicon
(Tecumsula, CA), CalBiochem (Carlsbad, CA), or Mole-
cular Probes (Eugene, OR). All other polyclonal and
monoclonal antibodies and immunodetection reagents
were purchased from Abcam (Cambridge, MA), Vector
Laboratories (Burlingame, CA), Upstate (Billerica, MA),
Chemicon (Temecula, CA), or Molecular Probes
(Eugene, OR). The insulin ultra-sensitive ELISA kit was
obtained from ALPCO Diagnostics (Salem, NH). Histo-
choice fixative was purchased from Amresco, Inc
(Solon, OH). Antibodies to tumor necrosis factor-a
(TNF-a) and interleukin-1b (IL-1b) were purchased
from Invitrogen (Carlsbad, CA). The Free Fatty Acid
Assay kit was purchased from Roche Applied Science
(Indianapolis, IN). Antibodies to GSK3b, and phospho-
GSK-3b (Ser9) were purchased from Cell Signaling
(Danvers, MA). The OxyBlot assay for measuring pro-
tein carbonylation and the Milliplex-MAP Rat Adipo-
nectin-Single Plex kit were purchased from Millipore
Corp (Billerica, MA). The Amplex Red Cholesterol
Assay Kit and Amplex UltraRed soluble fluorophore
were purchased from Invitrogen (Carlsbad, CA). Maxi-
Sorb 96-well plates used for ELISAs were from Nunc
(Thermo Fisher Scientific; Rochester, NY). The MDA-
586 kit to measure malondialdehyde was purchased
from Oxis International, Inc. (Foster City, CA). The
anti-IL6 and Leptin ELISA kits were from Peprotech
(Rocky Hill, NJ). The TopCount NXT and ATP Lite
assay kit were from Perkin-Elmer (Waltham, MA).
Superblock-TBS, horseradish peroxidase conjugated
antibodies, and SuperSignal Enhanced Chemilumines-
cence Reagent were from Pierce Chemical Co (Rockford,
IL). QIAzol Lysis Reagent for RNA extraction and
QuantiTect SYBR Green PCR Mix were obtained from
Qiagen, Inc (Valencia, CA). The AMV 1
st Strand cDNA
Synthesis kit was purchased from Roche Applied
Science (Indianapolis, IN). The Serum Triglyceride
Determination kit and synthetic oligonucleotides used in
quantitative polymerase chain reaction (qPCR) assays
were purchased from Sigma-Aldrich Co (St. Louis, MO).
Fine chemicals were purchased from CalBiochem (Carls-
bad, CA) or Sigma-Aldrich (St. Louis, MO).
Experimental Model
P o s t n a t a ld a y3( P 3 )L o n gE v a n sr a tp u p s( m e a nb o d y
weight 10 g) were given 3 alternate day intra-peritoneal
(i.p.) injections of 20 μg NDEA or vehicle. Upon weaning,
male rats (N = 8-10 per group) were pair-fed for 8 weeks
with high fat (HFD) or low fat (LFD) chow diets. The
HFD supplied 60% of the kcal in fat (54% from lard, 6%
from soybean oil), 20% in carbohydrates, and 20% in pro-
tein, whereas the LFD supplied 10% of the kcal in fat
(4.4% from lard, 5.6% from soybean oil), 70% in carbohy-
drates, and 20% in protein. Rats were weighed weekly,
and food consumption was monitored daily. After an
overnight fast (14 hours), rats were sacrificed by i.p.
injection of pentobarbital (120 mg/kg). Blood and cere-
bella were harvested immediately. Blood or serum was
used to measure glucose, insuli n ,c h o l e s t e r o l ,t r i g l y c e r -
ides, and free fatty acid levels, as previously described
[45,46]. Cerebella were harvested for histopathological,
biochemical, and molecular studies. For histopathology,
tissue samples were immersion fixed in Histochoice and
embedded in paraffin. Histological sections (8-μmt h i c k )
were stained with Luxol Fast Blue, Hematoxylin, and
Eosin (LHE) and examined under code. Adjacent sections
were immunostained to detect glial fibrillary acidic pro-
tein (GFAP), ubiquitin, or 4-hydroxy-2-nonenal (HNE) as
indices of neurodegeneration and oxidative stress as
described elsewhere [79]. For molecular and biochemical
assays, cerebella were snap-frozen in a dry ice-methanol
bath and stored at -80°C. We studied cerebellar tissue
because the cerebellum: 1) requires intact insulin/IGF
signaling to maintain its structural and functional integ-
rity [80,81]; 2) is severely damaged by i.c.-STZ mediated
neurodegeneration [19,22]; 3) although relatively spared,
it been shown to be a target of neurodegeneration in AD
[57-59,82]; and 4) postmortem human studies demon-
strated that AD cerebella exhibit insulin resistance [30].
Our experimental protocol was approved by the Institu-
tional Animal Care and Use Committee at Lifespan-
Rhode Island Hospital, and conforms to the guidelines
set by the National Institutes of Health.
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR) Assays of Gene Expression
RNA was reverse transcribed using random oligodeoxy-
nucleotide primers. The cDNAs of interest were ampli-
fied by PCR using gene specific primers (Table 1), and
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Primer Direction Sequence (5’ → 3’) Position (mRNA) Amplicon Size (bp)
Insulin For TTC TAC ACA CCC AAG TCC CGT C 145 135
Insulin Rev ATC CAC AAT GCC ACG CTT CTG C 279
Insulin Receptor For TGA CAA TGA GGA ATG TGG GGA C 875 129
Insulin Receptor Rev GGG CAA ACT TTC TGA CAA TGA CTG 1003
IGF-I For GAC CAA GGG GCT TTT ACT TCA AC 65 127
IGF-I Rev TTT GTA GGC TTC AGC GGA GCA C 191
IGF-I Receptor For GAA GTC TGC GGT GGT GAT AAA GG 2138 113
IGF-I Receptor Rev TCT GGG CAC AAA GAT GGA GTT G 2250
IGF-II For CCA AGA AGA AAG GAA GGG GAC C 763 95
IGF-II Rev GGC GGC TAT TGT TGT TCA CAG C 857
IGF-II Receptor For TTG CTA TTG ACC TTA GTC CCT TGG 1066 91
IGF-II Receptor Rev AGA GTG AGA CCT TTG TGT CCC CAC 1156
IRS-1 For GAT ACC GAT GGC TTC TCA GAC G 604 134
IRS-1 Rev TCG TTC TCA TAA TAC TCC AGG CG 737
IRS-2 For CAA CAT TGA CTT TGG TGA AGG GG 255 109
IRS-2 Rev TGA AGC AGG ACT ACT GGC TGA GAG 263
IRS-4 For ACC TGA AGA TAA GGG GTC GTC TGC 2409 132
IRS-4 Rev TGT GTG GGG TTT AGT GGT CTG G 2540
ChAT For TCA CAG ATG CGT TTC ACA ACT ACC 478 106
ChAT Rev TGG GAC ACA ACA GCA ACC TTG 583
AChE For TTC TCC CAC ACC TGT CCT CAT C 420 123
AChE Rev TTC ATA GAT ACC AAC ACG GTT CCC 542
APP For GCA GAA TGG AAA ATG GGA GTC AG 278 199
APP Rev AAT CAC GAT GTG GGT GTG CGT C 476
Tau For CGC CAG GAG TTT GAC ACA ATG 244 65
Tau Rev CCT TCT TGG TCT TGG AGC ATA GTG 308
SPTLC-1 For CTAACCTTGGGCAAATCGAA 2581 96
SPTLC-1 Rev TGAGCAGGGAGAAGGGACTA 2676
SPTLC-2 For GGA CAG TGT GTG GCC TTT CT 1823 50
SPTLC-2 Rev TCA CTG AAG TGT GGC TCC TG 1872
CERS-1 For TGC GTG AAC TGG AAG ACT TG 947 98
CERS-1 Rev CTT CAC CAG GCC ATT CCT TA 1044
CERS-2 For CTC TGC TTC TCC TGG TTT GC 698 82
CERS-2 Rev CCA GCA GGT AGT CGG AAG AG 779
CERS-4 For CGA GGC AGT TTC TGA AGG TC 1240 72
CERS-4 Rev CCA TTG GTA ATG GCT GCT CT 1311
CERS-5 For GAC AGT CCC ATC CTC TGC AT 1254 92
CERS-5 Rev GAG GTT GTT CGT GTG TGT GG 1345
UGCG For GAT GCT TGC TGT TCA CTC CA 2682 67
UGCG Rev GCT GAG ATG GAA GCC ATA GG 2748
SMPD-1 For CAG TTC TTT GGC CAC ACT CA 1443 65
SMPD-1 Rev CGG CTC AGA GTT TCC TCA TC 1507
SMPD-3 For TCT GCT GCC AAT GTT GTC TC 2704 98
SMPD-3 Rev CCG AGC AAG GAG TCT AGG TG 2801
*Abbreviations: IGF = insulin-like growth factor; IRS = insulin receptor substrate; ChAT = choline acetyltransferase; AChE = acetylcholinesterase; APP = amyloid
precursor protein; SPTLC = serine palmitoyltransferase; CERS = ceramide synthase; UGCG = UDP-glucose ceramide glucosyltransferae; SMPD = sphingomyelin
phosphodiesterase; bp = base pair.
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realplex instrument and software (Eppendorf AG, Ham-
burg, Germany) [45,83]. Relative mRNA abundance was
calculated from the ratios of specific mRNA to 18S
measured in the same samples, and those data were
used for inter-group statistical comparisons. Control
studies included analysis of: 1) template-free reactions;
2) RNA that had not been reverse transcribed; 3) RNA
samples pre-treated with DNAse I; 4) samples treated
with RNAse A prior to the reverse transcriptase reac-
tion; and 5) genomic DNA. All assays were performed
in triplicate.
Enzyme-Linked Immunosorbant Assay (ELISA)
Tissue homogenates were prepared in radioimmunopre-
cipitation assay buffer containing protease and phospha-
tase inhibitors, as previously described [46]. Direct
ELISAs were performed in 96-well Maxisorb plates [79].
In brief, proteins (40 ng/100 μl) adsorbed to well bot-
toms by over night incubation at 4°C, were blocked for
3 hours with 3% BSA in Tris buffered saline (TBS), then
incubated with primary antibody (0.1-1.0 μg/ml) for 1
hour at room temperature. Immunoreactivity was
detected with horseradish peroxidase (HRP)-conjugated
secondary antibody (1:10000) and Amplex Red soluble
fluorophore [79]. Amplex Red fluorescence was mea-
sured (Ex 579/Em 595) in a SpectraMax M5 microplate
reader (Molecular Devices Corp., Sunnyvale, CA). Nega-
tive control reactions included substitutions with non-
relevant primary or secondary antibodies, and omission
of primary or secondary antibody. Immunoreactivities
were normalized to protein content as determined with
the NanoOrange Protein Quantification assay.
Statistical Analysis
Data depicted in the graphs and tables represent the
means ± S.E.M.’s for each group, with 8-10 samples
included per group. Inter-group comparisons were made
using one-way ANOVA and Bonferroni’sm u l t i p l e
comparisons test for significance. Statistical analyses
were performed using the GraphPad Prism 5 software
(GraphPad Software, Inc., San Diego, CA). Software gen-
erated significant P-values are shown in the graphs or
included in the tables.
Results
Effects of NDEA and HFD on Serum Biomarkers of T2DM
(Table 2)
Mean body weights were higher in HFD fed relative to
LFD fed rats. Mean fasting blood glucose and serum
insulin concentrations were significantly lower in the
LFD+VEH treated control group compared with all
other groups. The mean levels of both serum glucose
and insulin were next higher in the LFD+NDEA group,
followed by the HFD group. The HFD+NDEA treated
rats had the highest mean serum glucose and insulin
levels. Correspondingly, serum leptin levels were signifi-
cantly elevated in the HFD+VEH and HFD+NDEA trea-
ted relative to both LFD+VEH and LFD+NDEA groups.
Serum adiponectin was lowest in the HFD+VEH group,
and the difference relative to the HFD+NDEA treated
group was statistically significant. Sera from rats in the
HFD+VEH and HFD+NDEA treated groups had signifi-
cantly lower mean triglyceride, free fatty acids, and cho-
lesterol levels compared with LFD+VEH and LFD
+NDEA treated groups. In addition, the serum free fatty
acid level was significantly lower in the LFD+NDEA
compared with LFD+VEH treated rats, whereas the tri-
glyceride and cholesterol levels were similar in the two
groups. Therefore, hyperglycemia, hyper-insulinemia,
and hyper-leptinemia were features of chronic HFD
feeding, and worsened by prior exposure to NDEA. In
addition, early NDEA exposure alone was sufficient to
cause mild but significant peripheral insulin resistance
manifested by hyperglycemia and hyper-insulinemia in
adults. In contrast, neither the NDEA exposure nor the
chronic HFD feeding caused hyper-lapidarian, indicating
that seemingly favorable serum lipid profiles can exist in
Table 2 High Fat Diet Feeding and NDEA Treatment Cause Type 2 Diabetes Mellitus
Assay LFD+VEH LFD+NDEA HFD+VEH HFD+NDEA F-Ratio P-Value
Body Wt (g) 265.100 ± 14.050 266.600 ± 19.970 315.300 ± 5.794 308.400 ± 15.110 3.42 0.04
Glucose (mg/dL) 111.5 ± 1.66 128.8* ± 4.31 137.6*** ± 2.39 150.8*** ξ ± 4.69 18.2 < 0.0001
Insulin (ng/ml) 0.0611 ± 0.017 0.163* ± 0.038 0.324** ± 0.074 0.581*** ξ ± 0.060 22.69 < 0.0001
Leptin 4.649 ± 0.789 4.775 ± 0.386 11.49*** ξ ± 0.678 15.73*** ξ ± 1.473 37.22 < 0.0001
Adiponectin 20864 ± 1454 25195 ± 3019 16819 ξ ± 1254 26635 ± 1962 3.36 0.048
Triglyceride (mg/ml) 0.399 ± 0.028 0.424 ± 0.005 0.173*** ξ ± 0.011 0.231*** ξ ± 0.032 38.2 < 0.0001
Free Fatty Acids (mM/mg prot) 0.150 ± 0.003 0.114* ± 0.018 0.081*** ξ ± 0.002 0.063*** ξ ± 0.010 21.9 < 0.0001
Cholesterol (mg/ml) 0.943 ± 0.024 0.986 ± 0.112 0.552*** ξ ± 0.051 0.748*** ξ ± 0.093 6.53 0.004
Serum samples obtained at sacrifice and after an over-night fast were studied. Inter-group comparisons were made using ANOVA with Bonferroni’s Multiple
Comparison Tests. For all measurements, df = 3/36. Asterisks reflect significant differences relative to the LFD+ Vehicle-treated (VEH) control group (*P < 0.05; **P
< 0.01; ***P < 0.001 relative to LFD+VEH). ξ = significant differences as follows: Glucose: P < 0.05 vs LFD+NDEA; Insulin: P < 0.001 vs LFD+NDEA; Adiponectin: P <
0.05 vs HFD+NDEA; Triglyceride: P < 0.001 vs LFD+NDEA; FFA: P < 0.001 vs LFD+NDEA; Cholesterol: P < 0.001 vs LFD+NDEA.
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Similar results have been reported previously, in which
the investigators generatedm o d e l sw i t hm u c hh i g h e r
doses of NDEA [84]. One potential explanation for this
paradox is that homeostatic mechanisms may have
shifted toward increased storage of lipids/triglycerides in
adipose tissue, skeletal muscle, and perhaps liver.
Further studies will probe this hypothesis.
Neuropathology of NDEA Exposure (Fig 1)
The LFD-fed, vehicle-treated control rats had cerebella
with complex foliation, tri-laminar cortical architecture
with richly populated granule and Purkinje cell layers,
and uniform white matter cores (Fig. 1-A1). HFD feed-
ing alone produced subtle changes characterized by
focal loss of Purkinje neurons (Fig. 1-A3). NDEA expo-
sure, with or without chronic HFD feeding, resulted in
loss of Purkinje cells (Figs. 1-A2, 1-A4) and variable
thinning of the granule cell layer. Immunohistochemical
staining demonstrated similar levels and distributions of
GFAP immunoreactivity in cells distributed in the gran-
ule layer of control (Fig 1-B1) and HFD-fed (Fig 1-B3)
rats, but reduced labeling in the NDEA-treated group
(Fig 1-B2), and increased GFAP immunoreactivity in the
NDEA+HFD treated group (Fig 1-B4). Control and
NDEA-treated rats had similarly very low levels of HNE
Figure 1 Cerebellar Degeneration in NDEA, HFD-Fed and NDEA+HFD Treated Rats. Long Evans rats were treated with 3 i.p. injections of
vehicle or NDEA (N = 12/group) on alternate days beginning on P3. From P21 (weaning), rats were fed with high fat (60% of calories) or low fat
(5% of calories) diets for 8 weeks, after which they were sacrificed to harvest cerebella for histopathological and immunohistochemical staining
studies. Cerebella were preserved in Histofix and paraffin-embedded sections (8 microns) were stained with (A1-A4) Luxol fast blue, H&E.
Adjacent sections were immunostained to detect (B1-B4) GFAP, (C1-C4) HNE, or (D1-D4) ubiquitin. Representative photomicrographs of cerebellar
cortex from (A1-D1) LFD+vehicle treated controls, (A2-D2) LFD+NDEA treated, (A3-D3) HFD+vehicle treated, and (A4-D4) HFD+NDEA treated rats
are shown. Immunohistochemical staining was performed using the ABC method, and revealed with DAB (brown precipitate)-see Experimental
Procedures. Sections were lightly counterstained with Hematoxylin (blue) to help reveal the tissue architecture. Cerebellar layers: ml = molecular
layer; pc = Purkinje cell layer; gc = granule cell layer; wm = white matter. Note focal pc loss in A2, and large zones of pc loss in A3 and A4.
(Original Magnifications = 400×).
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whereas rats fed with HFDs, with or without NDEA
exposure, had increased HNE immunoreactivity in white
matter cores (Figs. 1-C3, 1-C4). In addition, the white
matter was more vacuolated, suggestive of increased
myelin degeneration, in these two groups. Ubiquitin
immunoreactivity was virtually undetectable in control
and NDEA-exposed cerebella (Figs. 1-D1, 1-D2), but
slightly increased in the Purkinje and granule cell layers
of HFD-fed cerebella (Fig. 1-D3). Rats exposed to
NDEA, and also chronically fed with the HFD, had pro-
minently increased ubiquitin immunoreactivity in Pur-
kinje cells, and diffusely increased labeling of fine cell
process in the granule and molecular layers of the cere-
bellar cortex (Fig. 1-D4). The increased ubiquitin and
HNE immunoreactivities in both cortex and white
matter suggest that oxidative injury associated with
NDEA + HFD feeding occurred in neuronal and glial
cell populations.
NDEA-Treatment Plus Chronic HFD Feeding Causes
Sustained Abnormalities in Gene Expression Including
Impairments in Insulin/IGF Signaling Mechanisms in the
Brain
We used qRT-PCR analysis to quantify long-term effects
of NDEA ± HFD exposure on amyloid precursor protein
(AbPP), Tau, choline acetyltransferase (ChAT), and
acetylcholinesterase (AChE), i.e. molecular indices of
neurodegeneration and cholinergic homeostasis. In addi-
tion, we measured gene expression corresponding to
insulin and IGF polypeptides and receptors, and insulin
receptor substrates (IRSs) that transmit signals required
for growth, survival, energy metabolism, and neuronal
plasticity downstream of the insulin and IGF receptors
(Table 3). Early NDEA exposure alone was sufficient to
significantly reduce the mean mRNA levels of AbPP
(P < 0.05), Tau (P < 0.01), insulin receptor (P < 0.001),
IGF-2 receptor (P < 0.01), and IRS-2 (P < 0.05) relative
to control (LFD+VEH). Chronic HFD feeding signifi-
cantly reduced ChAT (P < 0.05) and IRS-1 (P < 0.01)
expression. HFD+NDEA reduced Tau (P < 0.01), ChAT
(P < 0.05), and insulin (P < 0.05), but had no significant
effect on the mean mRNA levels of AChE, IGF-1, IGF-
2, IGF-1 receptor, or IRS-4. Therefore, it appears that
the inhibitory effects of NDEA on insulin receptor, IGF-
2 receptor, and IRS-2 were muted by the chronic HFD
feeding. Moreover, the main effect of NDEA, irrespec-
tive of HFD feeding, was to reduce tau gene expression,
whereas chronic HFD feeding, irrespective of NDEA
treatment, significantly inhibited ChAT. The only
unique effect of HFD+NDEA treatment was to reduce
insulin gene expression in the brain.
Effects of NDEA and Chronic HFD Feeding on Protein
Biomarkers of Neurodegeneration (Fig 2)
ELISAs were used to measure sustained effects of NDEA
treatment and/or chronic HFD feeding on Tau, phos-
pho-Tau, AbPP, AbPP-Ab, ChAT, and AChE levels in
brain tissue. Early limited exposure to NDEA signifi-
cantly reduced the mean levels of pTau (P < 0.001),
AbPP (P < 0.01), ChAT (P < 0.05), and AChE (P < 0.01)
relative to the levels measured in LFD+VEH treated
controls. In addition, in the LFD+VEH group, the
mean levels of pTau (P < 0.001), AbPP (P < 0001), and
AChE (P < 0.05) were significantly lower than in the
chronic HFD-fed group. Chronic HFD feeding alone
Table 3 Effects of High Fat Diet and NDEA Exposure on Biomarkers of Insulin and IGF Resistance in the Cerebellum
mRNA LFD+VEH LFD+NDEA HFD+VEH HFD+NDEA F-Ratio P-Value
AbPP 7.007 ± 0.828 3.129* ξ ± 0.309 8.960 ± 1.542 6.796 ± 1.287 4.918 0.006
Tau 12.230 ± 1.098 6.586** ξ ± 1.329 11.230 ± 1.248 7.284** ξ ± 0.500 6.612 0.001
AChE 2.829 ± 0.178 4.171 ± 0.698 3.719 ± 0.618 3.562 ± 0.412
ChAT 0.701 ± 0.045 0.780 ± 0.122 0.519* ± 0.039 0.485* ± 0.037 3.524 0.020
Insulin 0.754 ± 0.048 0.617 ± 0.047 0.691 ± 0.040 0.584* ± 0.038 3.065 0.040
IGF-1 0.957 ± 0.119 0.717 ± 0.179 0.558 ± 0.063 0.630 ± 0.060
IGF-2 12.000 ± 1.800 15.460 ± 4.684 17.930 ± 6.163 11.140 ± 2.453
Insulin R 17.090 ± 1.547 7.59*** ξ ± 0.808 16.590 ± 1.572 16.170 ± 1.685 9.824 < 0.001
IGF-1R 5.031 ± 0.525 4.331 ± 0.982 3.052 ± 0.297 4.511 ± 0.392
IGF-2R 5.677 ± 0.548 2.641** ξ ± 0.432 5.289 ± 0.693 4.797 ± 0.466 6.201 0.002
IRS-1 5.559 ± 0.411 4.167 ± 0.725 3.254** ± 0.207 5.276 ± 0.505 4.532 0.009
IRS-2 7.701 ± 0.509 4.834* ± 0.934 5.278 ± 0.286 7.571 ± 1.198 3.403 0.028
IRS-4 0.135 ± 0.022 0.104 ± 0.024 0.119 ± 0.019 0.091 ± 0.017
Gene expression was measured by qRT-PCR with results normalized to 18S rRNA (see Methods). Values correspond to mRNA/18S × 10
-6. Inter-group comparisons
were made using ANOVA and the post-hoc Bonferroni multiple comparison test. For all measurements, df = 3/36. Asterisks (*P < 0.05; **P < 0.01; ***P < 0.001)
reflect significant differences relative to LFD controls. ξ = significant differences as follows: AbPP: P < 0.05 vs HFD+VEH and HFD+NDEA; Tau: P < 0.01 vs
HFD+VEH; ChAT: P < 0.05 vs LFD+NDEA; Insulin R: P < 0.001 vs HFD+VEH and HFD+NDEA; IGF-2R: P < 0.001 vs HFD+VEH and HFD vs NDEA; IRS-1: P < 0.01 vs
HFD+NDEA and P < 0.05 vs LFD+NDEA.
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Page 7 of 16Figure 2 Effect of HFD feeding on molecular indices of AD-type neurodegeneration. Cerebellar protein homogenates were used to
measure (A) Tau; (B) phospho (p)-Tau; (C) AbPP, (D) AbPP-Ab, (E) choline acetyltransferase (ChAT); or (F) acetylcholinesterase (AChE) by direct
binding ELISA. Immunoreactivity was detected with HRP-conjugated secondary antibody and Amplex Red soluble fluorophor. Fluorescence light
units (FLU) were measured (Ex 579 nm/Em 595 nm) in a Spectromax M5, and results were normalized to sample protein content in the wells.
Box plots depict mean, range ± S.D. of results (N = 8-10/group). Inter-group comparisons were made using ANOVA with the post-hoc Bonferroni
multiple comparisons test of significance. Significant P-values are indicated within the panels.
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Page 8 of 16(HFD+VEH) significantly reduced pTau (P < 0.01) and
ChAT (P < 0.001) relative to control, whereas early
NDEA exposure plus later chronic HFD feeding signifi-
cantly reduced Tau (P < 0.001), pTau (P < 0.001), ChAT
(P < 0.001), and AChE (P < 0.001) relative to control
and chronic HFD fed rats. In addition, the mean levels
of Tau (P < 0.001) and ChAT (P < 0.001) were signifi-
cantly lower in the HFD+NDEA compared with the
LFD+NDEA treated group. Therefore, the major adverse
effects of chronic HFD feeding were to significantly
reduce pTau and ChAT immunoreactivities relative to
control, while early limited exposure to NDEA signifi-
cantly reduced pTau, AbPP, ChAT, and AChE. Com-
bined exposure to HFD and NDEA produced similar
effects as NDEA-treatment alone with regard to the
reductions in pTau, AbP P ,a n dA C h E ,b u th a da d d i t i v e
or synergistic effects with regard to reductions in Tau
and ChAT immunoreactivity.
Effects of NDEA and Chronic HFD Feeding on Protein
Biomarkers of Oxidative Injury and Inflammation (Fig 3)
ELISAs were used to measure sustained effects of early
limited NDEA treatment and/or chronic HFD feeding on
glycogen synthase kinase 3b (GSK-3b), pGSK-3b (Ser 9),
GFAP, glyceraldehydes-3-phosphate dehydrogenase
(GAPDH), HNE, Nytrotyrosine, (N-Tyr), b-Actin, IL-1b,
TNF-a, and IL-6 immunoreactivities. In addition, we mea-
sured MDA and protein carbonylation levels in brain. The
objective was to assess oxidative stress and biomarkers of
injury. Early limited exposure to NDEA had no significant
effect on any of the indices measured relative to control.
Chronic HFD feeding significantly increased the mean
levels of pGSK-3b, GFAP, and N-Tyr relative to all other
groups (P < 0.05 or better). Combined early limited NDEA
exposure plus later chronic HFD feeding significantly
reduced the mean levels of GSK-3b and GFAP relative to
all other groups (P < 0.01 or better), and pGSK-3b and b-
Actin relative to the LFD+VEH control (both P < 0.05)
and HFD+VEH (both P < 0.001) treated groups. The find-
ing of proportionally greater reductions in pGSK-3b rela-
tive to total GSK-3b in the HFD+NDEA group indicates
that the combined treatments caused a net increase in
activated GSK-3b. The mean levels of HNE were similar
in the HFD+VEH and HFD+NDEA groups, and both were
significantly higher than in the LFD+VEH and LFD
+NDEA groups (P < 0.01). We did not detect significant
inter-group differences with respect to MDA (Fig 3), pro-
tein carbonylation, or IL-1b,T N F - a, and IL-6 immunor-
eactivities (data not shown).
NDEA-Mediated Increases in Pro-Ceramide Gene
Expression
We investigated the potential role of pro-ceramide genes as
mediators of NDEA ± HFD associated neurodegeneration
because ceramides: 1) can be generated in brain [85-88]; 2)
cause cytotoxicity and insulin resistance [83,88]; and 3) are
increased in brains with neurodegeneration [85,89-91]. We
measured mRNA levels of ceramide synthases (CER), UDP
glucose ceramide glycosyltransferase (UGCG), serine
palmitoyltransferase (SPTLC), and sphingomyelin phos-
phodiesterases (SMPD), due to their demonstrated rele-
vance to neurodegeneration [45,83]. HFD feeding alone
increased the mean levels of UGCG (P < 0.01) and
SPTLC2 (P < 0.01), whereas NDEA treatment significantly
reduced CER2 (P < 0005), CER5 (P < 0.001), and SPTLC1
(P < 0.01), but increased UGCG (P < 0.05) mRNA levels
(Fig 4). HFD+NDEA feeding significantly increased CER2
(P < 0.005), UGCG (P < 0.001), SMPD1 (P < 0.05), SMPD3
(P < 0.001), and SPTLC2 (P < 0.05), but decreased CER5
(P < 0.001) relative to control. The unique effects of
HFD+NDEA feeding comparedw i t he i t h e rt r e a t m e n t
alone were to significantly increase CER2, SMPD1 and
SMPD3 gene expression (Fig 4). NDEA and/or chronic
HFD feeding did not significantly alter CER1 or CER4 gene
expression.
Discussion
Our studies examined the degree to which limited
early life NDEA exposure exacerbates the effects of
chronic HFD feeding on the development of T2DM and
neurodegeneration. The importance of this work is that
morbidity and mortality rates from T2DM and neurode-
generation have soared over the past several decades,
suggesting that exposures rather than genetics dictate
their etiologies. Our over-arching hypothesis is that
shifts in lifestyles and economics have led us to chroni-
cally consume excess fat, and get exposed to agents that
cause insulin resistance. Consideration given to poten-
tial pathogenic agents was focused by the experimental
evidence showing that STZ, a nitrosamine-related
chemical, is mutagenic in high doses [14], but causes
insulin-resistance diseases at lower levels or more
limited durations of exposure, including early in life
[15-22,92]. While STZ is generally not available to
consumers, nitrosamines and related compounds are
widely present in our environment and contaminate
food sources. Therefore, we entertained the hypothesis
that either limited or chronic low-level exposures to
nitrosamines account for the observed shifts in morbid-
ity and mortality from insulin resistance diseases. More-
over, given the clear role of high dietary fat intake as a
mediator of obesity, T2DM, or cognitive impairment,
we proposed that the combined effects of HFD and
NDEA exposure may act additively or synergistically to
cause insulin resistance diseases, including T2DM and
neurodegeneration.
W eg e n e r a t e da ni nv i v om o d e li nw h i c hr a t
pups were treated with NDEA at doses that were 5- to
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Page 9 of 16500-fold lower than the cumulative doses needed to
produce cancer in experimental animals [93-96], and
beginning in early adolescence, we pair-fed the rats with
either high (60%) or low (5%) fat containing diets. The
NDEA doses were selected to be far below those needed
for carcinogenesis and were based on empirical studies
demonstrating absence of acute toxic effects in the rats.
Longer durations of NDEA exposure were not used in
order to avoid the possibility that the cumulative doses
would lead to malignant transformation. The use of
young rats enabled us to compare results with previous
observations in the STZ model [81]. Moreover, longitu-
dinal studies of nuns revealed that neuro-cognitive defi-
cits precede the onset of dementia by decades [97,98],
Figure 3 Effect of HFD feeding on molecular indices of oxidative stress and neurodegeneration. Cerebellar protein homogenates were
used to measure (A) GSK-3b; (B) phospho (p)-GSK-3b; (C) GFAP; (D) GAPDH; (E) HNE; (F) malondialdehyde, MDA; (G) Nitrotyrosine, N-TYR; or (H)
b-Actin; by direct binding ELISA. Immunoreactivity was detected with HRP-conjugated secondary antibody and Amplex Red soluble fluorophor.
Fluorescence light units (FLU) were measured (Ex 579 nm/Em 595 nm) in a Spectromax M5, and results were normalized to sample protein
content in the wells. Box plots depict mean, range ± S.D. of results (N = 8-10/group). Inter-group comparisons were made using ANOVA with
the post-hoc Bonferroni multiple comparisons test of significance. Significant P-values are indicated within the panels.
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the pathogenesis of AD, perhaps through gene imprint-
ing. Although chronic HFD feeding and limited NDEA
exposure increased body weight and caused T2DM/per-
ipheral insulin resistance with fasting hyperglycemia,
hyper-insulinemia, and hyper-leptinemia [99,100], the
rats were not obese and they did not have hyper-lipide-
mia. Instead, the serum lipid profile was favorable, con-
sistent with a previous report of a related experimental
model [84].
We focused our investigations on the cerebellum
because the cerebellum can be adversely affected in AD,
as well as other neurodegenerative diseases [47,50,
53,56,59,60,65,68,69,71], and cerebellar degeneration
causes cognitive impairment [49,57-59,62,63,66,67,72].
Previous studies demonstrated significant structural,
functional, and metabolic abnormalities in AD cerebella
[57-59,82], including insulin and IGF resistance [30],
similar to the findings in more traditional targets of AD,
i.e. cortical and limbic structures. Finally, by focusing on
o n eb r a i nr e g i o n ,w ew e r ea b l et oi n v e s t i g a t ean o v e l
concept concerning potential additive or synergistic
effects of double-hits, i.e. nitrosamine plus HFD expo-
sures, on neurodegeneration in general.
Although both NDEA and HFD feeding caused struc-
tural injury and impaired gene expression in ways that
could cause insulin/IGF resistance in the brain, their
specific effects were not identical. The main effect of
N D E A ,w i t ho rw i t h o u tH F Df e e d i n g ,w a st or e d u c e
mRNA levels of insulin receptor, IGF-2 receptor, and
IRS-2, which would have impaired signaling at the
receptor level, and downstream through IRS-2, one of
main docking proteins responsible for transmitting sur-
vival, growth, metabolism, and plasticity pathway signals
[80,81]. Correspondingly, NDEA treatment inhibited tau
and ChAT, which are regulated by insulin and IGF [81],
Figure 4 Effect of HFD feeding on pro-ceramide gene expression in brain. Total RNA extracted from cerebellar tissue was reverse
transcribed using random oligodeoxynucleotide primers, and the resulting cDNA templates were used in qRT-PCR assays to measure (A)
Ceramide synthase (CER)1, (B) CER2, (C) CER4, (D) CER5, (E) UDP-glucose ceramide glycoysltransferase (UGCG), (F) sphingomyelin
phosphodiesterase 1 (SMPD1), (G) SMPD3, (H) Serine palmitoyltransferase 1 (SPTLC1), and (I) SPTLC2. The mRNA levels were normalized to 18S
rRNA measured in the same templates. Graphs depict the mean, range ± S.D. of gene expression levels (N = 8 per group). Inter-group
comparisons were made using ANOVA with the post-hoc Bonferroni multiple comparisons test of significance. Significant P-values are indicated
within the panels.
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tau, a major structural prote i ni nC N Sn e u r o n s ,c o u l d
result in cytoskeletal collapse and synaptic disconnec-
tion. Alternatively, the finding could reflect neuronal
loss associated with neurodegeneration. The reduced
levels of ChAT reflect deficits in acetylcholine homeos-
tasis that contribute to cognitive impairment with
neurodegeneration [101,102]. Correspondingly, in preli-
minary studies, we detected evidence of significant
spatial learning and memory deficits in NDEA and
NDEA+HFD treated rats by Morris Water Maze testing
(Additional file 1, Table S1). The potential contribution
of non-cerebral, specifically cerebellar degeneration
to cognitive impairment was demonstrated in human
subjects with PD, whereby mild cognitive impairment
was found to be associated with reduced nicotinic
acetylcholine receptor binding in the cerebellum and
brainstem [103].
In previous studies using a mouse model of diet-
induced obesity [45,46], we showed that chronic HFD
feeding causes brain insulin resistance [46]. Similarly,
herein we demonstrated that the HFD-fed rats had
reduced levels of brain IRS-1 mRNA, which would have
been sufficient to cause brain insulin resistance due to
impaired transmission of insulin receptor activated sig-
nals; correspondingly, ChAT expression was reduced. In
a d d i t i o n ,H F Df e e d i n gi n c r e a s e dG F A P ,H N E ,a n dN -
Tyr immunoreactivities, consistent with findings in pre-
vious studies [45,46], and providing further evidence
that HFD feeding contributes to neurodegeneration by
increasing gliosis/astrocyte activation and oxidative
stress with lipid peroxidation, as occur in AD. The find-
ing that chronic HFD feeding did not significantly alter
tau or AbPP expression also supports our previous con-
clusion that HFD feeding contributes to, but is not suffi-
cient to cause AD-type neurodegeneration [45,46].
The combined effect of early, limited NDEA exposure
plus chronic HFD feeding significantly reduced insulin
and ChAT mRNA levels, and ChAT, AChE, GSK-3b,
and pGSK-3b immunoreactivities. In addition, tau and
ChAT expression levels were lowest in the HFD+NDEA
group. Since tau and ChAT are regulated by insulin/IGF
signaling [81], the impairment in insulin gene expression
was likely pivotal in mediating these effects of HFD
+NDEA exposure. In the HFD+NDEA group, both
GSK-3b and pGSK-3b levels were reduced, but relative
reductions were greater for pGSK-3b compared with
total GSK-3b, reflecting a net relative increased in GSK-
3b activity, similar to the findings in AD and PD in
humans [29,30,104]. Therefore, HFD+NDEA treated rats
exhibited persistent brain oxidative stress associated
with increased levels of HNE (lipid peroxidation), N-
Tyr, and GSK-3b activity. Although the NDEA exposure
was delivered within a brief window during the human
equivalent of childhood or early adolescence, its adverse
effects on the brain were sustained into adulthood, simi-
lar to the findings with respect to the i.c.-STZ model
[19,22]. Conceivably, such prolonged and possibly
progressive deficits may occur because nitrosamines
promote formation of DNA and protein adducts
[105-107] that can serve as persistent sources of oxida-
tive stress, and cause further DNA damage and protein
dysfunction.
Recently, we demonstrated a role for ceramide-
mediated neurodegeneration in a model of diet-induced
obesity with T2DM [45], and showed that in vitro cera-
mide exposure causes neurodegeneration with impair-
ments in neuronal viability, energy metabolism and
insulin/IGF signaling mechanisms [83], consistent with
previous reports [45,83,85,88-90,108-110]. Moreover,
other investigators have demonstrated significantly
increased levels of ceramides and other sphingolipids in
brains with neurodegeneration [76,90,110-114]. There-
fore, we measured pro-ceramide mRNA levels to deter-
mine if the HFD or NDEA-associated neurodegeneration
and insulin/IGF resistance were likely mediated by
increased brain ceramide levels. Those studies demon-
strated strikingly increased expression of several genes
regulating ceramide production via both de novo bio-
synthesis or sphingomyelin degradation pathways in
NDEA-treated rats, irrespective of chronic HFD feeding.
Since NDEA is lipid soluble [115,116] and can cross the
blood-brain barrier [117], it is probable that the neurode-
generation with insulin/IGF resistance associated with
limited NDEA exposure was mediated by direct and per-
sistent neurotoxic effects of compound.
Conclusions
In conclusion, we have demonstrated that limited early
exposure to sub-mutagenic doses of NDEA causes
T2DM and neurodegeneration with impairments in
insulin/IGF signaling mechanisms, and deficits in choli-
nergic and neuronal cytoskeletal gene and protein
expression in brain, whereas chronic HFD feeding alone
produces more restrictive deficits in insulin/IGF signal-
ing mechanisms with reduced ChAT expression and
increased oxidative stress. The combined exposures
caused overlapping structural and molecular abnormal-
ities that were additive with regard to the breadth of
insulin/IGF signaling molecules that were impaired, and
synergistic with respect to the degrees in which ChAT
and tau expression were reduced and pro-ceramide
genes increased. Since experimentally, exposure to neu-
rotoxic ceramides produces similar effects, their
increased levels in cerebrospinal fluid could serve as bio-
markers of insulin-resistance mediated neurodegenera-
tion. Finally, the findings suggest that our insulin
resistance disease epidemics are linked to sub-mutagenic
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Page 12 of 16exposures to nitrosamines and related compounds, com-
bined with chronic consumption of high fat content
foods, indicating that these diseases are preventable.
Additional file 1: Effects of HFD and NDEA on Learning: Morris
Water Maze Test. This supplementary table provides data showing
adverse effects of NDEA exposure, chronic HFD feeding or both
treatments on spatial learning and memory using the Morris Water Maze
test.
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